AN

AngioDynamics, Inc.

ANGOHealthcareNASDAQ

Medical Instruments & Supplies · Last scanned Jul 18, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$320.2M
+9.5% YoY
Net Income
-$36.7M
-8.1% YoY
EBITDA
$626,000
-64.0% YoY
Free Cash Flow
$21.8M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11 MACD Negative CrossoverHistogram -0.0580, negative momentum
Jul 10 MACD Negative CrossoverHistogram -0.0393, negative momentum
About AngioDynamics, Inc.

Headquartered within the healthcare sector, AngioDynamics, Inc. focuses on Medical Instruments & Supplies services and products. AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. Valued at $558.4M, ANGO is a small-cap name in its sector. The company operates through Med Tech and Med Device segments.

Key stats
Market Cap$558.4M
Fwd P/E-300.22
EPS$-0.84
Beta0.34
52W Change+55.5%
ROE-20.8%
Analysis

The balance sheet looks solid with $53.9M in cash comfortably exceeding the $11.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $21.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -20.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $338.8M (2023) to $320.2M (2026).

The relatively low beta of 0.34 suggests ANGO is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ANGO.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms